Cost‐effectiveness of first‐line systemic therapies for unresectable hepatocellular carcinoma

Documenti analoghi

• Trends in first‐line monotherapy and combination therapy for hypertension in UK primary care
  di: Kyle Johnson, et al.
  Pubblicazione: (2025)
• Mitigating subtherapeutic cabozantinib exposure after prior mitotane therapy in adrenocortical carcinoma: Pharmacological boosting with cobicistat
  di: Annemieke M. Peters van Ton, et al.
  Pubblicazione: (2025)
• Efficacy, safety and cost‐effectiveness of CAR‐T therapy
  di: Emina Karahmet Sher, et al.
  Pubblicazione: (2026)
• Cost–utility of lifileucel in patients with advanced melanoma after progression on immune checkpoint inhibitors And targeted therapies: a middle‐income economy setting
  di: Svetlana Obrenovic, et al.
  Pubblicazione: (2025)
• Cost‐effectiveness of DPYD genotyping prior to fluoropyrimidine‐based treatment for colorectal cancer in Wales
  di: Catrin O. Plumpton, et al.
  Pubblicazione: (2026)